Cullinan Therapeutics (CGEM) News Today $8.12 +0.12 (+1.44%) As of 10:12 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Equities Analysts Issue Forecasts for CGEM Q1 EarningsMarch 4 at 3:09 AM | americanbankingnews.comFY2029 Earnings Forecast for CGEM Issued By WedbushCullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Analysts at Wedbush issued their FY2029 earnings estimates for shares of Cullinan Therapeutics in a research report issued on Thursday, February 27th. Wedbush analyst R. Driscoll expects that the company will earn ($2.22) per share for theMarch 3 at 3:46 AM | marketbeat.comQ1 Earnings Estimate for CGEM Issued By William BlairCullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Cullinan Therapeutics in a note issued to investors on Thursday, February 27th. William Blair analyst M. Phipps forecasts that the company will postMarch 3 at 3:12 AM | marketbeat.comHC Wainwright Reaffirms Buy Rating for Cullinan Therapeutics (NASDAQ:CGEM)HC Wainwright reaffirmed a "buy" rating and set a $33.00 target price on shares of Cullinan Therapeutics in a research note on Friday.March 1 at 8:25 AM | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells $41,754.35 in StockCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jeffrey Alan Jones sold 4,895 shares of the company's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $8.53, for a total value of $41,754.35. Following the transaction, the insider now directly owns 174,164 shares in the company, valued at approximately $1,485,618.92. This represents a 2.73 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.February 28, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) CEO Nadim Ahmed Sells 12,529 SharesCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) CEO Nadim Ahmed sold 12,529 shares of the business's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $8.53, for a total transaction of $106,872.37. Following the completion of the transaction, the chief executive officer now owns 430,621 shares of the company's stock, valued at approximately $3,673,197.13. This trade represents a 2.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.February 28, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Announces Earnings ResultsCullinan Therapeutics (NASDAQ:CGEM - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.02.February 28, 2025 | marketbeat.comInsider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells 4,895 Shares of StockFebruary 28, 2025 | insidertrades.comAdaptimmune Therapeutics (NASDAQ:ADAP) vs. Cullinan Therapeutics (NASDAQ:CGEM) Head to Head SurveyFebruary 28, 2025 | americanbankingnews.comCullinan Therapeutics: Q4 Earnings SnapshotFebruary 27, 2025 | sfgate.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Cullinan Management (CGEM)February 27, 2025 | markets.businessinsider.comCullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 27, 2025 | globenewswire.comCullinan Therapeutics (NASDAQ:CGEM) Sets New 52-Week Low - Should You Sell?Cullinan Therapeutics (NASDAQ:CGEM) Hits New 12-Month Low - Here's What HappenedFebruary 24, 2025 | marketbeat.comCullinan Therapeutics to Participate in Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comCullinan Therapeutics (NASDAQ:CGEM) Reaches New 52-Week Low - Time to Sell?Cullinan Therapeutics (NASDAQ:CGEM) Hits New 12-Month Low - Here's WhyFebruary 19, 2025 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Short Interest UpdateCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 8,730,000 shares, a drop of 10.7% from the January 15th total of 9,780,000 shares. Currently, 23.7% of the shares of the company are short sold. Based on an average trading volume of 555,600 shares, the days-to-cover ratio is currently 15.7 days.February 19, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month Low - What's Next?Cullinan Therapeutics (NASDAQ:CGEM) Hits New 52-Week Low - Here's WhyFebruary 12, 2025 | marketbeat.comCullinan Therapeutics Inc.February 12, 2025 | wsj.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of "Buy" by BrokeragesShares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) have received a consensus rating of "Buy" from the seven brokerages that are covering the stock, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12 month pFebruary 11, 2025 | marketbeat.comLeerink Partnrs Has Strong Estimate for CGEM FY2024 EarningsCullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for Cullinan Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now expects that the company will earn ($2.88) per shFebruary 10, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for CGEM Q1 Earnings?Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Cullinan Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the compFebruary 7, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Sees Strong Trading Volume - What's Next?Cullinan Therapeutics (NASDAQ:CGEM) Sees Unusually-High Trading Volume - Here's What HappenedFebruary 6, 2025 | marketbeat.comHC Wainwright Brokers Decrease Earnings Estimates for CGEMCullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Research analysts at HC Wainwright lowered their FY2025 earnings estimates for Cullinan Therapeutics in a report released on Wednesday, January 29th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($2February 3, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth PlansJanuary 31, 2025 | finance.yahoo.comWhat is HC Wainwright's Estimate for CGEM Q1 Earnings?Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Cullinan Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst E. White anticipates that the company will postJanuary 31, 2025 | marketbeat.comCullinan Management (CGEM) Receives a Buy from BTIGJanuary 30, 2025 | markets.businessinsider.comCullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech ConferenceJanuary 30, 2025 | finance.yahoo.comCullinan Management Receives ‘Buy’ Rating as Phase 2b Study Success and Taiho Partnership Boost ProspectsJanuary 29, 2025 | markets.businessinsider.comCullinan Therapeutics price target raised to $33 from $28 at H.C. WainwrightJanuary 29, 2025 | markets.businessinsider.comCullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up Following Analyst UpgradeCullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up on Analyst UpgradeJanuary 29, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Cullinan Therapeutics (NASDAQ:CGEM) Stock PriceHC Wainwright increased their price objective on Cullinan Therapeutics from $28.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday.January 29, 2025 | marketbeat.comTaiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior TherapyJanuary 28, 2025 | prnewswire.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of "Buy" from AnalystsShares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) have earned an average recommendation of "Buy" from the seven brokerages that are currently covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 montJanuary 17, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Hits New 12-Month Low - What's Next?Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 1-Year Low - What's Next?January 15, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3% - Should You Sell?Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3% - Time to Sell?January 14, 2025 | marketbeat.comCullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLCJanuary 10, 2025 | seekingalpha.comCullinan Therapeutics: Casting A Wide Net With Their PipelineJanuary 8, 2025 | seekingalpha.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 4,000 SharesJanuary 8, 2025 | insidertrades.comJennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) StockCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 4,000 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $12.51, for a total value of $50,040.00. Following the completion of the sale, the insider now directly owns 95,760 shares of the company's stock, valued at approximately $1,197,957.60. This represents a 4.01 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.January 7, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 5.4% - Here's WhyCullinan Therapeutics (NASDAQ:CGEM) Trading Down 5.4% - Here's WhyJanuary 6, 2025 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up - Time to Buy?Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up - Time to Buy?January 2, 2025 | marketbeat.comShort Interest in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Increases By 5.3%Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 9,650,000 shares, an increase of 5.3% from the November 30th total of 9,160,000 shares. Based on an average daily trading volume, of 496,100 shares, the short-interest ratio is currently 19.5 days. Approximately 26.0% of the shares of the company are short sold.January 1, 2025 | marketbeat.comGeode Capital Management LLC Buys 231,935 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Geode Capital Management LLC increased its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 23.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,208,421 shares of the companDecember 29, 2024 | marketbeat.comNadim Ahmed Sells 8,400 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) StockDecember 28, 2024 | insidertrades.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) CEO Sells $99,708.00 in StockCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) CEO Nadim Ahmed sold 8,400 shares of the stock in a transaction on Tuesday, December 24th. The stock was sold at an average price of $11.87, for a total value of $99,708.00. Following the transaction, the chief executive officer now owns 263,150 shares of the company's stock, valued at $3,123,590.50. The trade was a 3.09 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.December 27, 2024 | marketbeat.comCullinan Therapeutics (NASDAQ:CGEM) Trading Down 2.9% - Should You Sell?Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 2.9% - Time to Sell?December 26, 2024 | marketbeat.comBarclays PLC Acquires 51,300 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)Barclays PLC lifted its holdings in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 26.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 248,614 shares of the companDecember 23, 2024 | marketbeat.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of "Buy" by AnalystsCullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) has been given a consensus rating of "Buy" by the seven research firms that are currently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month target priceDecember 23, 2024 | marketbeat.comCullinan Therapeutics chief scientific officer sells $53,547 in stockDecember 23, 2024 | investing.comCullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by State Street CorpState Street Corp boosted its position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) by 20.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,337,222 shares of the company's stock aDecember 21, 2024 | marketbeat.com Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEM Media Mentions By Week CGEM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGEM News Sentiment▼0.720.70▲Average Medical News Sentiment CGEM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGEM Articles This Week▼214▲CGEM Articles Average Week Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HRMY News BLTE News VERA News TVTX News GLPG News IDYA News JANX News TARS News IRON News KNSA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGEM) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
